• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AbbVie, Calico launch R&D collaboration for age-related diseases

AbbVie, Calico launch R&D collaboration for age-related diseases

September 4, 2014
CenterWatch Staff

Chicago-based AbbVie and Calico, a California-based Google-founded R&D company, have announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer.

Calico is a Google-backed life sciences company led by Arthur D. Levinson, Ph.D., former chairman and CEO of Genentech, and Hal V. Barron, M.D., former executive vice president and chief medical officer of Genentech.

The companies will accelerate the availability of new therapies for age-related diseases. Calico will use its scientific expertise to establish a world-class R&D facility in the San Francisco Bay Area, with a focus on drug discovery and early drug development. AbbVie will provide scientific and clinical development support and its commercial expertise to bring new discoveries to market.

"This collaboration demonstrates our commitment to exploring new areas of medicine and innovative approaches to drug discovery and development that augments our already robust pipeline," said Richard A. Gonzalez, chairman of the board and CEO, AbbVie. 

"Our relationship with AbbVie is a pivotal event for Calico, whose mission is to develop life-enhancing therapies for people with age-related diseases. It will greatly accelerate our efforts to understand the science of aging, advance our clinical work and help bring important new therapies to patients everywhere," said Art Levinson, CEO and founder of Calico.

AbbVie and Calico will each initially provide up to $250 million to fund the collaboration, with the potential for both sides to contribute an additional $500 million. Calico will be responsible for research and early development during the first five years and continue to advance collaboration projects through phase IIa for a 10-year period. AbbVie will support Calico in its early R&D efforts and, following completion of phase IIa studies, will have the option to manage late-stage development and commercial activities.

Both parties will share costs and profits equally.

Michael Severino, M.D., executive vice president, R&D, and chief scientific officer, AbbVie, said, "Our broad R&D experience and capabilities will complement Calico's biotechnology expertise and innovative scientific approaches. Together, we are confident that we will bring new therapeutic solutions to patients."

Calico expects to begin filling critical positions immediately and plans to establish a substantial team of scientists and research staff in the San Francisco Bay Area.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing